Posted by Michael Wonder on 30 Dec 2022
MediWound announces FDA approval of NexoBrid for the treatment of severe thermal burns in adults
29 December 2022 - Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the US in the second quarter of 2023.
MediWound today announced that the US FDA has approved NexoBrid (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.
